Authors
Koichi Kamei, Isao Miyairi, Kenji Ishikura, Masao Ogura, Kensuke Shoji, Takanori Funaki, Reiko Ito, Katsuhiro Arai, Jun Abe, Toshinao Kawai, Masafumi Onodera, Shuichi Ito
Publication date
2018/5/1
Journal
The Journal of Pediatrics
Volume
196
Pages
217-222. e1
Publisher
Mosby
Description
Objective
To conduct a prospective study to evaluate the immunogenicity and safety of live attenuated vaccines in patients with nephrotic syndrome receiving immunosuppressive agents.
Study design
Patients with nephrotic syndrome receiving immunosuppressive agents with negative or borderline antibody titers (virus-specific IgG levels <4.0) against measles, rubella, varicella, and/or mumps fulfilling the criteria of cellular and humoral immunity were enrolled. Virus-specific IgG levels were measured using an enzyme immunoassay. The primary endpoint was the seroconversion rate (ie, achievement of virus-specific IgG levels ≥4.0) at 2 months after vaccination. Virus-specific IgG levels at 1 year, breakthrough infections (wild-type infections), and adverse events were also evaluated.
Results
A total of 116 vaccinations were administered to 60 patients. Seroconversion rates were 95.7% for measles, 100% for rubella …
Scholar articles
K Kamei, I Miyairi, K Ishikura, M Ogura, K Shoji… - The Journal of Pediatrics, 2018